Viewing Study NCT02921802

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:04 AM
Ignite Modification Date: 2026-02-26 @ 12:42 AM
Study NCT ID: NCT02921802
Status: COMPLETED
Last Update Posted: 2022-06-14
First Post: 2016-09-30
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
Sponsor: Celgene
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Multiple Myeloma View
None Myelodysplastic Syndromes View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Teratogenicity View
None Thrombocytopenia and haemorrhage View
None Neutropenia and infection View
None Venous thromboembolism View
None Allergic reactions View
None Diarrhoea or constipation View
None Peripheral neuropathy View
None Cardiac failure View
None Arrhythmia View
None Renal failure View
None Myocardial infarction View
None Interstitial lung disease View
None Tumour lysis syndrome View
None Transformation from myelodysplastic syndrome to acute myeloid leukemia View